Compare Campbell Soup Co. (CPB) vs Citius Pharmaceuticals Inc (CTXR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Campbell Soup Co. vs Citius Pharmaceuticals Inc — how do they compare? Campbell Soup Co. trades at $22.64 (market cap $6.78B), while Citius Pharmaceuticals Inc trades at $0.72 (market cap $20.01M). The key difference: Campbell Soup Co. is far larger — about 338.8× Citius Pharmaceuticals Inc's market cap, and Campbell Soup Co. pays a 6.87% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CPB | CTXR | |
|---|---|---|
Market Cap | $6.78B | $20.01M |
Sector | Consumer Staples | Health |
52-Week High | $34.03 | $1.82 |
52-Week Low | $20.00 | $0.48 |
Enterprise Value | $13.38B | $16.23M |
Dividend Yield | 6.87% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Campbell's (CPB) trades at $22.56, up 0.6% with bullish technical signals and mixed fundamentals. The stock shows strong valuation metrics with P/E of 11.1 and P/S of 0.7, while recent earnings beat expectations in Q1 2026. Revenue growth remains modest at $10.3B in 2025, though net margins compressed to 5.9%. Technical indicators suggest bullish momentum with support at $22 and resistance at $23.
CPB offers a compelling 7% dividend yield supported by stable cash flows, but faces margin pressure and analyst skepticism with only 3% buy ratings. The company's cost-saving initiatives and new product launches provide potential upside, though competitive pressures and consumer spending trends remain key risks for sustained growth.
CTXR is trading at $0.7126, up 5.26% today, with strong technical momentum showing bullish moving average signals. The company shows significant revenue growth potential with LYMPHIR commercialization expanding, though currently operates at substantial losses with a -823% net income margin. Analyst sentiment remains overwhelmingly positive with 83% buy ratings, reflecting optimism about the oncology pipeline and recent commercial progress.
The investment case hinges on successful LYMPHIR commercialization offsetting current losses, with strong institutional support providing runway. Key risks include execution challenges in scaling operations and the capital-intensive nature of biopharmaceutical development. The stock presents high-risk, high-reward potential for investors comfortable with clinical-stage biotech volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Campbell Soup Co.
With a history that dates back around 150 years, Campbell Soup is now a leading manufacturer and marketer of branded convenience food products, most notably soup. The firm's product assortment includes well-known brands like Campbell's, Pace, Prego, Swanson, V8, and Pepperidge Farm. Following the sale of its international snacking operations, which wrapped in calendar 2019, the firm derives nearly all of its sales from its home turf. Campbell has made a handful of acquisitions to reshape its product mix the past few years, including the tie-up with Snyder's-Lance (completed in March 2018), which enhances its exposure to the faster-growing on-trend snack food aisle, complementing its Pepperidge Farm lineup.
Read more on CPB →About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →
